Plasma naltrexone during opioid detoxification

Tim McDonald, Rich Berkowitz, William E. Hoffman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Orogastric naltrexone is used for opioid detoxification, but it is not known how gastric absorption affects plasma concentrations of the drug. We measured plasma naltrexone during orogastric naltrexone, given in repeated doses of 12.5 mg, 25 mg, 50 mg and 50 mg. Plasma naltrexone was measured after each naltrexone dose. The increase in plasma naltrexone was highly variable between patients during orogastric administration. Adequate detoxification was questioned in 4 of 10 patients because plasma naltrexone did not increase above 5 ng/ml. There was a negative correlation between plasma naltrexone and the presence of withdrawal symptoms on the day after the procedure (r = −0.78, P < 0.05). These results show that the increase in plasma naltrexone is variable during orogastric administration and this may impair successful detoxification.

Original languageEnglish (US)
Pages (from-to)59-64
Number of pages6
JournalJournal of Addictive Diseases
Volume19
Issue number4
DOIs
StatePublished - Nov 10 2000

Fingerprint

Naltrexone
Opioid Analgesics
Substance Withdrawal Syndrome

Keywords

  • Antagonist
  • Detoxification
  • Naltrexone
  • Opiate

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Plasma naltrexone during opioid detoxification. / McDonald, Tim; Berkowitz, Rich; Hoffman, William E.

In: Journal of Addictive Diseases, Vol. 19, No. 4, 10.11.2000, p. 59-64.

Research output: Contribution to journalArticle

McDonald, T, Berkowitz, R & Hoffman, WE 2000, 'Plasma naltrexone during opioid detoxification', Journal of Addictive Diseases, vol. 19, no. 4, pp. 59-64. https://doi.org/10.1300/J069v19n04_06
McDonald, Tim ; Berkowitz, Rich ; Hoffman, William E. / Plasma naltrexone during opioid detoxification. In: Journal of Addictive Diseases. 2000 ; Vol. 19, No. 4. pp. 59-64.
@article{ec2272a5cd3844d2b0629bfd4ef5207b,
title = "Plasma naltrexone during opioid detoxification",
abstract = "Orogastric naltrexone is used for opioid detoxification, but it is not known how gastric absorption affects plasma concentrations of the drug. We measured plasma naltrexone during orogastric naltrexone, given in repeated doses of 12.5 mg, 25 mg, 50 mg and 50 mg. Plasma naltrexone was measured after each naltrexone dose. The increase in plasma naltrexone was highly variable between patients during orogastric administration. Adequate detoxification was questioned in 4 of 10 patients because plasma naltrexone did not increase above 5 ng/ml. There was a negative correlation between plasma naltrexone and the presence of withdrawal symptoms on the day after the procedure (r = −0.78, P < 0.05). These results show that the increase in plasma naltrexone is variable during orogastric administration and this may impair successful detoxification.",
keywords = "Antagonist, Detoxification, Naltrexone, Opiate",
author = "Tim McDonald and Rich Berkowitz and Hoffman, {William E.}",
year = "2000",
month = "11",
day = "10",
doi = "10.1300/J069v19n04_06",
language = "English (US)",
volume = "19",
pages = "59--64",
journal = "Journal of Addictive Diseases",
issn = "1055-0887",
publisher = "Routledge",
number = "4",

}

TY - JOUR

T1 - Plasma naltrexone during opioid detoxification

AU - McDonald, Tim

AU - Berkowitz, Rich

AU - Hoffman, William E.

PY - 2000/11/10

Y1 - 2000/11/10

N2 - Orogastric naltrexone is used for opioid detoxification, but it is not known how gastric absorption affects plasma concentrations of the drug. We measured plasma naltrexone during orogastric naltrexone, given in repeated doses of 12.5 mg, 25 mg, 50 mg and 50 mg. Plasma naltrexone was measured after each naltrexone dose. The increase in plasma naltrexone was highly variable between patients during orogastric administration. Adequate detoxification was questioned in 4 of 10 patients because plasma naltrexone did not increase above 5 ng/ml. There was a negative correlation between plasma naltrexone and the presence of withdrawal symptoms on the day after the procedure (r = −0.78, P < 0.05). These results show that the increase in plasma naltrexone is variable during orogastric administration and this may impair successful detoxification.

AB - Orogastric naltrexone is used for opioid detoxification, but it is not known how gastric absorption affects plasma concentrations of the drug. We measured plasma naltrexone during orogastric naltrexone, given in repeated doses of 12.5 mg, 25 mg, 50 mg and 50 mg. Plasma naltrexone was measured after each naltrexone dose. The increase in plasma naltrexone was highly variable between patients during orogastric administration. Adequate detoxification was questioned in 4 of 10 patients because plasma naltrexone did not increase above 5 ng/ml. There was a negative correlation between plasma naltrexone and the presence of withdrawal symptoms on the day after the procedure (r = −0.78, P < 0.05). These results show that the increase in plasma naltrexone is variable during orogastric administration and this may impair successful detoxification.

KW - Antagonist

KW - Detoxification

KW - Naltrexone

KW - Opiate

UR - http://www.scopus.com/inward/record.url?scp=0033652739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033652739&partnerID=8YFLogxK

U2 - 10.1300/J069v19n04_06

DO - 10.1300/J069v19n04_06

M3 - Article

C2 - 11110065

AN - SCOPUS:0033652739

VL - 19

SP - 59

EP - 64

JO - Journal of Addictive Diseases

JF - Journal of Addictive Diseases

SN - 1055-0887

IS - 4

ER -